---
title: "Elamipretide (SS-31)"
canonical_url: https://peptidelibrary.app/library/elamipretide
description: "Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Elamipretide (SS-31)

Elamipretide (SS-31), also called MTP-131 or Bendavia, is an FDA-approved mitochondria-targeted tetrapeptide in the Mitochondrial Peptide class. Elamipretide is a cell-permeable aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane in a manner not dependent on membrane potential, so it accumulates even in depolarised, dysfunctional mitochondria.

Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required.

Also known as: MTP-131, Bendavia, Forzinity, Szeto-Schiller peptide.

Categories: Fat Loss, Muscle/Recovery, Longevity.

## Classification

- Type: FDA-approved mitochondria-targeted tetrapeptide
- Mechanism class: Mitochondrial Peptide
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Elamipretide is a cell-permeable aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane in a manner not dependent on membrane potential, so it accumulates even in depolarised, dysfunctional mitochondria. It binds cardiolipin, the signature phospholipid of that membrane, which is required for the structural organisation of cristae and for the assembly and efficiency of the electron transport chain supercomplexes. By stabilising cardiolipin it improves cristae architecture and electron transfer efficiency and reduces electron leak, lowering reactive oxygen species production at source rather than scavenging radicals after formation. In Barth syndrome the underlying tafazzin defect impairs cardiolipin remodelling directly, which is the rationale for its use there.

Targets: Cardiolipin, Inner mitochondrial membrane.

Origin: Synthetic aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2).

## Properties

- Sequence: D-Arg-Dmt-Lys-Phe-NH2
- Molecular formula: C32H49N9O5
- Molecular weight: 639.8 g/mol
- CAS number: 736992-21-5
- Half-life: ~4–5 h (iv) in human studies
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 3
- Controlled human trials: 1
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. FORZINITY (elamipretide hydrochloride) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults and paediatric patients with Barth syndrome weighing at least 30 kg. Muscle strength [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)
2. NCT05162768 — Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Barth Syndrome. Controlled human trial. Population: Subjects with Barth syndrome (n=102). Efficacy and safety in Barth syndrome [Source](https://clinicaltrials.gov/study/NCT05162768)
3. NCT03891875 — ReCLAIM-2 Study to Evaluate Safety, Efficacy and Pharmacokinetics of Elamipretide. Human study (early or uncontrolled). Population: Patients with dry AMD and geographic atrophy (n=176). Safety, efficacy and pharmacokinetics [Source](https://clinicaltrials.gov/study/NCT03891875)
4. NCT01572909 — Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury. Human study (early or uncontrolled). Population: Patients with ST-elevation myocardial infarction (n=300). Reduction of reperfusion injury [Source](https://clinicaltrials.gov/study/NCT01572909)

### Registered trials

- [NCT05162768](https://clinicaltrials.gov/study/NCT05162768)
- [NCT03891875](https://clinicaltrials.gov/study/NCT03891875)
- [NCT01572909](https://clinicaltrials.gov/study/NCT01572909)

## Safety

Side effects: Injection-site reactions; Eosinophilia reported in development; Headache.

Risks: Accelerated approval — clinical benefit still being confirmed; Indication is narrow (Barth syndrome ≥30 kg).

Contraindications: Hypersensitivity to elamipretide.

Human safety basis: FDA prescribing information

## Regulatory status

Elamipretide (SS-31) is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Elamipretide (SS-31)?

Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required. Elamipretide is a cell-permeable aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane in a manner not dependent on membrane potential, so it accumulates even in depolarised, dysfunctional mitochondria. It binds cardiolipin, the signature phospholipid of that membrane, which is required for the structural organisation of cristae and for the assembly and efficiency of the electron transport chain supercomplexes.

### How does Elamipretide (SS-31) work?

Elamipretide is a cell-permeable aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane in a manner not dependent on membrane potential, so it accumulates even in depolarised, dysfunctional mitochondria. It binds cardiolipin, the signature phospholipid of that membrane, which is required for the structural organisation of cristae and for the assembly and efficiency of the electron transport chain supercomplexes.

### Is Elamipretide (SS-31) FDA approved?

Yes. Elamipretide (SS-31) is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Elamipretide (SS-31)?

Reported half-life for Elamipretide (SS-31) is ~4–5 h (iv) in human studies. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Elamipretide (SS-31)?

Elamipretide (SS-31) has the sequence D-Arg-Dmt-Lys-Phe-NH2, giving a chain of 5 amino acids. Its molecular formula is C32H49N9O5.

### Is Elamipretide (SS-31) banned in sport?

Elamipretide (SS-31) is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

## References

- [FDA accelerated approval — Forzinity](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome)
- [DailyMed — Forzinity](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)
- [Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial — Orphanet J Rare Dis, 2024](https://pubmed.ncbi.nlm.nih.gov/39574155/)
- [Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial — Neurology, 2023](https://pubmed.ncbi.nlm.nih.gov/37268435/)
- [Elamipretide: First Approval — Drugs, 2026](https://pubmed.ncbi.nlm.nih.gov/41335372/)
- [Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — Int J Mol Sci, 2025](https://pubmed.ncbi.nlm.nih.gov/39940712/)
- [Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report — Mol Genet Metab, 2025](https://pubmed.ncbi.nlm.nih.gov/40816230/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
